力生制药：2025年度业绩预告

Group 1 - The company, Lisheng Pharmaceutical, announced an expected net profit attributable to shareholders of 400 million to 440 million yuan for the fiscal year 2025, indicating a growth of 116.77% to 138.44% compared to the previous year [2]